International Journal of Advance Research Publication and Reviews

Vol 1, Issue 3, pp 21-39, November 2024

AI Driven Precision Oncology: Predictive Biomarker Discovery and Personalized Treatment Optimization Using Genomic Data

Anil Kumar

Department of Computer Science, Maharishi International University, USA

ABSTRACT

Precision oncology has revolutionized cancer treatment by leveraging genomic data to develop targeted therapies tailored to individual patients. Artificial intelligence (AI), particularly machine learning and deep learning models, has emerged as a powerful tool for predictive biomarker discovery and personalized treatment optimization. This paper explores the role of AI-driven methodologies in identifying predictive biomarkers, stratifying patients based on molecular profiles, and optimizing treatment regimens to improve therapeutic efficacy while minimizing adverse effects. Through high-dimensional genomic analysis, AI algorithms can uncover hidden patterns in multi-omics datasets, including gene expression, mutations, and epigenetic modifications, to predict treatment responses and disease progression. Reinforcement learning and neural network-based approaches enable adaptive treatment strategies, allowing for real-time therapeutic adjustments based on evolving patient-specific genomic landscapes. Additionally, AI-driven computational frameworks integrate clinical and genomic data to enhance precision medicine initiatives, reducing trial-and-error treatment approaches and improving patient outcomes. This study examines the latest advancements in AI-driven precision oncology, highlighting successful applications in biomarker discovery, drug repurposing, and response prediction for immunotherapy and chemotherapy. Furthermore, we address key challenges, including data privacy concerns, model interpretability, and the need for robust validation in clinical settings. A comparative analysis of AI-based personalized treatment models versus traditional clinical decision-making underscores the transformative potential of AI in oncology. Future directions emphasize refining AI models for real-time clinical application, integrating multi-omics data for enhanced predictive accuracy, and addressing ethical considerations in AI-driven cancer treatment.

Keywords: Artificial Intelligence, Precision Oncology, Predictive Biomarkers, Genomic Data, Personalized Cancer Therapy, Machine Learning

1.INTRODUCTION

1.1 Overview of Precision Oncology

Precision oncology represents a paradigm shift in cancer treatment, evolving from conventional chemotherapy to targeted and personalized therapeutic strategies. Traditional chemotherapy, though effective in reducing tumor burden, lacks specificity, often resulting in systemic toxicity and adverse side effects [1]. Over time, advancements in molecular

biology and cancer genomics have enabled the identification of tumor-specific genetic mutations, leading to the development of targeted therapies that selectively inhibit oncogenic pathways while minimizing harm to normal tissues [2]. The introduction of monoclonal antibodies, small-molecule inhibitors, and immunotherapies has significantly improved treatment efficacy and patient survival rates in various malignancies, including lung, breast, and colorectal cancers [3].

The integration of genomic data has been a cornerstone in advancing precision medicine, allowing clinicians to stratify patients based on their tumor's molecular profile. Next-generation sequencing (NGS) and liquid biopsy techniques have facilitated comprehensive genetic profiling, enabling real-time monitoring of tumor evolution and treatment response [4]. The identification of predictive biomarkers, such as HER2 in breast cancer and EGFR mutations in non-small cell lung cancer, has revolutionized therapeutic decision-making by guiding the selection of targeted agents tailored to individual patients [5]. Furthermore, large-scale genomic databases, such as The Cancer Genome Atlas (TCGA), have provided valuable insights into cancer heterogeneity, aiding in the discovery of novel drug targets and resistance mechanisms [6]. As precision oncology continues to evolve, the integration of artificial intelligence (AI) is playing an increasingly vital role in optimizing cancer diagnosis, prognosis, and treatment selection [7].

1.2 Role of AI in Precision Oncology

AI has emerged as a transformative force in precision oncology, enhancing cancer diagnosis, prognostic prediction, and therapeutic decision-making through advanced computational techniques. Machine learning algorithms analyze vast datasets of histopathological images, radiological scans, and genomic profiles to identify subtle patterns associated with cancer progression and treatment response [8]. AI-powered diagnostic tools, such as convolutional neural networks (CNNs), have demonstrated remarkable accuracy in detecting malignancies in digital pathology slides, improving early cancer detection and reducing diagnostic variability among pathologists [9]. Additionally, AI-driven radiomics models extract quantitative imaging biomarkers from medical scans, enabling non-invasive tumor characterization and personalized treatment planning [10].

In treatment selection, AI aids in predicting patient responses to targeted therapies and immunotherapies by integrating multi-omic data, including genomic, transcriptomic, and proteomic profiles. Deep learning models, such as recurrent neural networks (RNNs) and transformer-based architectures, analyze patient-specific molecular signatures to recommend personalized therapeutic regimens, optimizing clinical outcomes [11]. Furthermore, reinforcement learning algorithms are being explored to develop adaptive treatment strategies that continuously refine therapeutic approaches based on real-time patient responses, paving the way for truly dynamic precision medicine [12].

Beyond diagnosis and treatment, AI contributes to drug discovery and clinical trial optimization by identifying potential drug candidates and matching patients to appropriate clinical studies. AI-driven drug repurposing platforms utilize knowledge graphs and natural language processing (NLP) to discover novel applications for existing drugs, accelerating the development of targeted cancer therapies [13]. Similarly, AI-powered clinical trial matching systems leverage patient genomic data to enroll eligible candidates in precision oncology trials, enhancing trial efficiency and patient outcomes [14]. As AI continues to integrate into oncology workflows, it holds the potential to revolutionize cancer care by enabling data-driven, personalized treatment strategies that maximize therapeutic efficacy while minimizing adverse effects [15].

1.3 Research Objectives and Scope

This study focuses on the role of AI in precision oncology, with a particular emphasis on predictive biomarker discovery and treatment optimization. Predictive biomarkers play a crucial role in identifying patients who are most likely to benefit from specific therapies, thereby minimizing ineffective treatments and reducing healthcare costs [16]. By leveraging AI-driven analytics, this research aims to uncover novel biomarker signatures that can guide treatment selection in cancers with high molecular heterogeneity [17]. Additionally, the study explores AI's role in optimizing treatment regimens by integrating real-world patient data, ensuring that therapeutic strategies remain adaptive and responsive to evolving tumor dynamics [18].

The study follows a multi-disciplinary approach, incorporating machine learning techniques, genomic data analysis, and clinical validation methods to assess AI's impact on precision oncology. Chapter 2 provides an overview of AI methodologies in oncology, including supervised and unsupervised learning, deep learning architectures, and reinforcement learning frameworks. Chapter 3 discusses AI-driven biomarker discovery, highlighting recent advancements in multi-omic integration and predictive modeling. Chapter 4 explores AI applications in treatment optimization, including dose adjustment strategies and combination therapy predictions. Chapter 5 examines challenges and ethical considerations in AI-driven oncology, addressing issues such as algorithmic bias, data privacy, and regulatory compliance. Finally, Chapter 6 concludes with key findings, future directions, and the potential for AI to further transform precision oncology in clinical practice [19].

2. AI IN PREDICTIVE BIOMARKER DISCOVERY

2.1 Fundamentals of Biomarker Discovery

Biomarkers are measurable indicators of biological processes, disease states, or treatment responses that play a critical role in precision oncology. They are broadly classified into predictive and prognostic biomarkers. Predictive biomarkers provide information about a patient's likelihood to respond to a specific therapy, guiding personalized treatment selection. For example, HER2 overexpression in breast cancer is a well-established predictive biomarker for trastuzumab therapy, ensuring targeted treatment for patients who are most likely to benefit [5]. On the other hand, prognostic biomarkers provide insights into disease progression independent of treatment, helping clinicians stratify patients based on risk factors. An example is Ki-67, a proliferation marker used to assess tumor aggressiveness across multiple cancer types [6].

The importance of biomarkers in cancer treatment and drug response cannot be overstated, as they allow for precise therapeutic interventions while minimizing unnecessary exposure to ineffective treatments. Molecular biomarkers, such as EGFR mutations in non-small cell lung cancer (NSCLC), enable the selection of targeted tyrosine kinase inhibitors (TKIs), significantly improving patient survival rates [7]. Additionally, immunotherapy biomarkers, such as PD-L1 expression levels and tumor mutation burden (TMB), help determine eligibility for immune checkpoint inhibitors, optimizing treatment efficacy in various malignancies [8]. As the landscape of oncology continues to evolve, artificial intelligence (AI) is playing an increasingly vital role in identifying novel biomarkers and refining existing ones for enhanced clinical utility [9].

2.2 AI Techniques for Biomarker Identification

AI-driven biomarker discovery relies on advanced computational techniques that analyze vast and complex biological datasets. Supervised learning approaches, such as support vector machines (SVMs) and random forests, are widely used to classify patients based on biomarker profiles, enabling precise patient stratification [10]. These models are trained on labeled datasets, allowing them to identify key molecular features associated with treatment response or disease progression. In contrast, unsupervised learning techniques, such as clustering algorithms (e.g., k-means and hierarchical clustering), uncover hidden patterns in genomic data, facilitating the discovery of novel biomarker subgroups without predefined labels [11].

Feature selection and dimensionality reduction methods play a crucial role in AI-driven biomarker identification by extracting the most relevant biological signals while eliminating redundant data. Principal component analysis (PCA) and autoencoders are commonly used to reduce the complexity of genomic datasets, improving computational efficiency without compromising accuracy [12]. Additionally, LASSO (Least Absolute Shrinkage and Selection Operator) regression is frequently employed to select key biomarkers with high predictive value, ensuring robust model performance [13]. These techniques enhance the interpretability of AI-generated biomarker signatures, making them more suitable for clinical applications.

The integration of multi-omics data is a fundamental aspect of AI-driven biomarker discovery, as it enables a comprehensive understanding of cancer biology. By combining genomic, transcriptomic, proteomic, and metabolomic

data, AI models can identify biomarkers that capture the intricate molecular interactions underlying tumor progression and treatment resistance [14]. Multi-omics integration is facilitated by deep learning architectures, such as convolutional neural networks (CNNs) and recurrent neural networks (RNNs), which process heterogeneous biological data and extract meaningful patterns with high precision [15]. Additionally, graph neural networks (GNNs) have been explored for pathway-based biomarker discovery, allowing AI models to map interactions between different molecular entities and predict potential therapeutic targets [16].

2.3 Case Studies and Clinical Applications

AI-based biomarker discovery has demonstrated significant success in multiple cancer types, including breast, lung, and colorectal cancers. In breast cancer, deep learning models trained on multi-omics data have successfully identified novel biomarkers associated with endocrine therapy resistance, paving the way for more personalized treatment strategies [17]. In NSCLC, AI-driven analysis of circulating tumor DNA (ctDNA) has enabled the early detection of actionable mutations, such as EGFR and ALK rearrangements, improving the selection of targeted therapies [18]. Similarly, in colorectal cancer, machine learning models have integrated genomic and histopathological data to refine biomarker panels for predicting chemotherapy response, enhancing treatment personalization [19].

Despite these successes, AI-driven biomarker identification faces several limitations. One major challenge is data variability, as biomarker discovery models often rely on heterogeneous datasets generated from different platforms, leading to inconsistencies in predictive performance [20]. Additionally, the lack of standardization in AI-driven biomarker validation poses challenges in clinical translation, as reproducibility remains a critical issue [21]. Another limitation is the potential for algorithmic bias, where AI models trained on specific patient populations may fail to generalize across diverse demographics, necessitating rigorous model validation across multi-ethnic cohorts [22].

Future directions for AI in biomarker validation focus on improving the interpretability and clinical trustworthiness of AI-generated biomarkers. Explainable AI (XAI) techniques, such as SHAP (Shapley Additive Explanations) and attention mechanisms, are being integrated into biomarker discovery models to provide transparent reasoning behind AI-driven predictions, fostering greater clinician acceptance [23]. Additionally, federated learning approaches, which enable collaborative AI model training across multiple institutions while preserving patient privacy, are being explored to enhance the robustness and generalizability of biomarker models [24]. As AI continues to evolve, its role in biomarker discovery and precision oncology is expected to expand, leading to more accurate, accessible, and clinically actionable cancer diagnostics and therapeutics [25].



Figure 1: Workflow of AI-driven predictive biomarker discovery

3. AI-DRIVEN PERSONALIZED TREATMENT OPTIMIZATION

3.1 Personalized Treatment Approaches in Oncology

Cancer treatment has evolved significantly from traditional one-size-fits-all approaches to personalized therapies driven by molecular and genetic profiling. Historically, chemotherapy and radiation therapy were the primary treatment options, targeting rapidly dividing cells without considering individual tumor characteristics [9]. While effective in some cases, these approaches often resulted in systemic toxicity and variable patient outcomes. The advent of targeted therapies and immunotherapies has transformed oncology by shifting toward treatments designed to exploit specific molecular alterations within tumors, improving both efficacy and safety [10].

Genomic profiling plays a pivotal role in tailoring cancer treatments, enabling clinicians to stratify patients based on tumor-specific genetic mutations, epigenetic modifications, and immune signatures. The development of high-throughput sequencing technologies, such as next-generation sequencing (NGS) and single-cell RNA sequencing, has facilitated the identification of actionable mutations, guiding the selection of targeted inhibitors and immune checkpoint blockade therapies [11]. For example, patients with EGFR-mutant non-small cell lung cancer (NSCLC) benefit from tyrosine kinase inhibitors (TKIs), while those with HER2-positive breast cancer respond favorably to trastuzumab [12]. Similarly, tumor mutation burden (TMB) and microsatellite instability (MSI) have emerged as key biomarkers for predicting responses to immunotherapies [13]. The integration of artificial intelligence (AI) further enhances precision oncology by analyzing vast datasets of molecular, imaging, and clinical information to optimize therapeutic decision-making [14].

3.2 AI Models for Personalized Therapy Selection

AI has significantly advanced personalized therapy selection by leveraging machine learning and deep learning algorithms to predict drug responses, optimize treatment strategies, and assist clinicians in decision-making.

Deep Learning Models for Drug Response Prediction

Deep learning models analyze multi-omics data, including genomic, transcriptomic, proteomic, and metabolomic information, to predict patient responses to specific cancer therapies [15]. Convolutional neural networks (CNNs) and transformer-based architectures process histopathological and radiological images, identifying tumor phenotypes that correlate with treatment outcomes [16]. Additionally, graph neural networks (GNNs) have been applied to model complex drug-target interactions, facilitating the identification of novel therapeutic agents for precision oncology [17]. AI-driven drug response models have been particularly successful in predicting sensitivity to chemotherapy, immunotherapy, and targeted therapies across various cancer types [18].

Reinforcement Learning for Adaptive Treatment Strategies

Reinforcement learning (RL) has emerged as a promising approach for optimizing adaptive cancer treatment strategies by continuously adjusting therapeutic regimens based on patient responses. RL models use a trial-and-error learning process to maximize treatment efficacy while minimizing toxicity, making them ideal for dynamic cancer management [19]. For example, multi-agent reinforcement learning (MARL) has been employed to personalize combination therapies by evaluating drug synergy and resistance patterns in real time [20]. In radiotherapy, RL-driven models optimize dose fractionation schedules to balance tumor control with normal tissue preservation, improving patient outcomes [21]. Additionally, AI-powered adaptive immunotherapy models adjust checkpoint inhibitor dosages based on immune system activity, enhancing treatment precision while reducing adverse effects [22].

AI-Driven Clinical Decision Support Systems

AI-driven clinical decision support systems (CDSS) integrate diverse patient data sources to assist oncologists in selecting the most effective treatment plans. These systems incorporate real-world evidence (RWE), including patient

medical records, clinical trial results, and biomarker profiles, to generate personalized therapeutic recommendations [23]. IBM Watson for Oncology and other AI-powered platforms use natural language processing (NLP) to extract relevant insights from scientific literature and match patients with appropriate clinical trials [24]. AI-based tumor board decision support platforms also facilitate multidisciplinary case discussions, providing oncologists with predictive analytics to improve collaborative decision-making [25].

3.3 Challenges and Limitations of AI in Personalized Oncology

Despite its potential, AI in personalized oncology faces significant challenges, including data heterogeneity, ethical concerns, and model interpretability, which must be addressed to enable widespread clinical adoption.

Data Heterogeneity and Lack of Standardized Datasets

AI models rely on large-scale, high-quality datasets to make accurate predictions, but significant heterogeneity exists in cancer data due to variations in sequencing techniques, imaging modalities, and patient demographics [26]. Differences in sample collection, preprocessing methods, and annotation standards create inconsistencies that hinder model generalization across institutions and patient populations [27]. Additionally, most publicly available cancer datasets, such as The Cancer Genome Atlas (TCGA), are biased toward specific ethnic and geographic groups, limiting the applicability of AI models to diverse populations [28]. Standardization efforts, such as harmonized multi-omics databases and federated learning approaches, are being explored to improve data quality and reduce bias in AI-driven oncology research [29].

Ethical Concerns and Regulatory Barriers in AI Adoption

The implementation of AI in oncology raises ethical and regulatory challenges related to patient privacy, informed consent, and algorithmic fairness. AI models trained on historical clinical data may perpetuate biases present in traditional cancer treatment practices, leading to disparities in therapeutic recommendations for underrepresented groups [30]. Additionally, the use of black-box AI systems in medical decision-making raises concerns about accountability and clinician responsibility, as errors in AI predictions could result in suboptimal or even harmful treatment choices [31].

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines for AI-driven medical technologies, emphasizing the need for transparent validation protocols and ongoing post-market surveillance [32]. However, achieving regulatory approval for AI-based precision oncology tools remains complex, as clinical trials must demonstrate consistent safety, efficacy, and real-world applicability before deployment in clinical settings [33]. Collaborative efforts between AI developers, oncologists, and regulatory agencies are crucial to establishing robust frameworks for the ethical deployment of AI in personalized cancer treatment [34].

Interpretability and Transparency of AI Models in Clinical Practice

A major limitation of AI in oncology is the lack of interpretability and transparency, which poses challenges in gaining clinician trust. Deep learning models, particularly CNNs and transformer networks, operate as black-box systems, making it difficult for oncologists to understand the rationale behind AI-generated recommendations [35]. This lack of explainability hinders AI adoption in clinical workflows, as physicians require interpretable decision-making frameworks to validate treatment suggestions and communicate findings to patients [36].

To address this issue, researchers are exploring explainable AI (XAI) techniques, such as attention mechanisms, feature attribution methods, and rule-based hybrid models, to improve model transparency [37]. SHAP (Shapley Additive Explanations) and LIME (Local Interpretable Model-Agnostic Explanations) provide visualizations of how AI models assign importance to specific genomic or clinical features, enhancing interpretability for oncologists [38]. Additionally, hybrid neuro-symbolic AI models, which combine deep learning with explicit rule-based reasoning, offer a structured and interpretable approach to cancer treatment decision-making [39].

AI-driven personalized oncology is revolutionizing cancer treatment by leveraging machine learning, deep learning, and reinforcement learning to optimize therapy selection and improve patient outcomes. By integrating multi-omics data and clinical decision support systems, AI enables precise, adaptive treatment strategies that tailor therapies to individual tumor profiles. However, challenges such as data heterogeneity, regulatory barriers, and model interpretability must be addressed to facilitate AI's widespread adoption in clinical oncology. Future advancements in federated learning, explainable AI, and regulatory standardization will be key to ensuring that AI-driven precision oncology fulfills its potential in transforming cancer care.



(Figure 2: Comparative performance of AI-based treatment selection vs. traditional clinical decision-making)

4. INTEGRATING MULTI-OMICS DATA FOR ENHANCED PRECISION ONCOLOGY

4.1 Multi-Omics Data in Oncology

Multi-omics data provides a comprehensive view of cancer biology by integrating multiple layers of molecular information, including genomics, transcriptomics, proteomics, and metabolomics. Each omics layer contributes unique insights into cancer pathophysiology, enhancing precision oncology approaches by identifying biomarkers, predicting treatment responses, and uncovering novel therapeutic targets [12].

Genomics focuses on DNA mutations, structural variations, and epigenetic modifications that drive cancer initiation and progression. High-throughput sequencing techniques, such as next-generation sequencing (NGS), allow for the identification of actionable mutations in genes like EGFR, BRCA1/2, and TP53, guiding targeted therapy selection [13].

Transcriptomics examines RNA expression patterns, providing insights into how genetic alterations impact gene activity. RNA sequencing (RNA-seq) enables the characterization of alternative splicing events, non-coding RNA regulation, and differential gene expression, which are critical for understanding tumor heterogeneity and drug resistance mechanisms [14].

Proteomics analyzes protein expression, modifications, and interactions, offering functional insights beyond genetic information. Post-translational modifications (PTMs), such as phosphorylation and glycosylation, regulate key oncogenic pathways and serve as potential therapeutic targets in cancers like HER2-positive breast cancer [15].

Metabolomics studies small-molecule metabolites, reflecting dynamic changes in tumor metabolism. Metabolite profiling has revealed cancer-specific metabolic reprogramming, such as increased glycolysis (Warburg effect), which can be exploited for therapeutic interventions [16].

By integrating these omics layers, researchers gain a holistic understanding of tumor biology, enabling the discovery of multi-omic biomarkers that provide superior predictive power compared to single-omics approaches [17]. AI-driven computational models play a crucial role in processing these complex datasets, making multi-omics integration feasible in precision oncology [18].

4.2 AI-Driven Integration of Multi-Omics Data

The integration of multi-omics data is computationally challenging due to the heterogeneity, high dimensionality, and complex interactions among different molecular layers. Machine learning (ML) approaches have been developed to fuse these datasets, improving cancer diagnosis, prognosis, and treatment selection [19].

Machine Learning Approaches for Fusing Heterogeneous Datasets

Supervised and unsupervised ML models are commonly used to integrate multi-omics data. Random forests, support vector machines (SVMs), and deep learning algorithms are applied to extract meaningful features from multi-omics datasets, reducing dimensionality while preserving critical biological signals [20].

Deep learning architectures, such as autoencoders and variational autoencoders (VAEs), are particularly effective in capturing latent patterns across omics layers. By learning hierarchical representations of molecular interactions, these models improve the identification of clinically relevant biomarkers and drug response predictions [21].

Another widely used approach is graph-based learning, where AI constructs molecular interaction networks linking genomic alterations to proteomic and metabolomic changes. Graph neural networks (GNNs) have shown promise in predicting oncogenic pathways and therapy resistance mechanisms by integrating diverse omics datasets [22].

AI Models for Predicting Treatment Outcomes from Multi-Omics Data

AI models enhance precision medicine by predicting patient responses to specific treatments using integrated multi-omics data. Recurrent neural networks (RNNs) and attention-based transformers analyze time-series multi-omics data, tracking tumor evolution and identifying treatment-sensitive subpopulations [23].

AI-driven multi-omics frameworks have been successfully used in:

- Breast cancer, where deep learning integrates genomic mutations, transcriptomic expression, and proteomic signatures to predict chemotherapy response [24].
- Lung cancer, where ML models identify metabolomic biomarkers associated with immunotherapy resistance, guiding treatment selection [25].
- Colorectal cancer, where AI-based transcriptomic analysis differentiates between high- and low-risk patients, improving prognostic accuracy [26].

By leveraging AI in multi-omics integration, researchers can develop patient-specific therapeutic strategies, reducing unnecessary treatments and minimizing adverse effects [27].

Use of Federated Learning in Decentralized Genomic Data Analysis

One of the major challenges in multi-omics research is the need for large, diverse datasets while maintaining patient privacy. Federated learning (FL) enables AI model training across multiple institutions without sharing raw patient data, preserving confidentiality while leveraging global genomic datasets [28].

FL models have been implemented in multi-omics analysis for:

- Collaborative biomarker discovery across hospitals, improving predictive accuracy without centralized data collection [29].

- Decentralized drug response modeling, ensuring AI models remain robust across diverse patient populations [30].
- Cross-institutional tumor evolution tracking, allowing real-time adaptation of precision oncology treatments [31].

Federated learning ensures that AI-driven multi-omics integration remains scalable, secure, and ethically compliant, paving the way for global collaboration in cancer research [32].

4.3 Current Limitations and Future Prospects

Despite its potential, AI-driven multi-omics integration faces several technical and clinical challenges that must be addressed to improve its reliability and clinical utility.

Technical Challenges in Multi-Omics Integration

1. Data Standardization Issues – Omics datasets originate from different experimental platforms, leading to inconsistencies in data formats, normalization methods, and batch effects. Without standardized preprocessing, AI models risk generating biased or non-reproducible results [33].
2. Computational Complexity – Multi-omics datasets are high-dimensional, requiring advanced AI architectures with high computational power. Training deep learning models on these datasets demands significant GPU resources, limiting accessibility for smaller research institutions [34].
3. Interpretability of AI Models – Most deep learning-based multi-omics models function as black-box systems, making it difficult for oncologists to validate AI-driven predictions. Explainable AI (XAI) methods, such as SHAP and LIME, are being explored to improve model transparency, ensuring that AI-generated biomarkers and treatment predictions are clinically interpretable [35].

Need for Improved Computational Frameworks and Better Validation Studies

To enhance the clinical applicability of AI-driven multi-omics research, future studies must focus on:

- Developing hybrid AI models that integrate symbolic reasoning with deep learning for more interpretable predictions.
- Expanding federated learning networks to create global AI-driven multi-omics collaborations.
- Validating AI-predicted biomarkers in prospective clinical trials to ensure real-world reliability.

Table 1: Comparison of AI Approaches for Single-Omics vs. Multi-Omics Data Integration

Feature	Single-Omics AI Models	Multi-Omics AI Models
Data Complexity	Low	High
Predictive Accuracy	Moderate	High
Interpretability	Higher (fewer variables)	Lower (requires XAI)
Computational Demand	Moderate	Very High
Therapeutic Insights	Limited to one layer	Comprehensive
Application in Oncology	Biomarker discovery	Treatment optimization

As AI-driven multi-omics research continues to evolve, overcoming these technical and validation challenges will be crucial to fully integrating AI into precision oncology and improving patient outcomes.

5. AI IN DRUG DISCOVERY AND REPURPOSING FOR CANCER TREATMENT

5.1 AI for Novel Drug Discovery

AI has revolutionized drug discovery by significantly reducing the time and cost associated with developing new therapeutics. Traditional drug discovery follows a linear and time-consuming process, often taking 10–15 years and costing billions of dollars to bring a single drug to market [16]. AI accelerates this process by streamlining hit identification, lead optimization, and preclinical validation using computational techniques such as machine learning (ML), deep learning (DL), and generative models [17].

One of AI's most promising applications in drug discovery is molecular structure prediction using generative adversarial networks (GANs) and variational autoencoders (VAEs). These models generate novel drug-like molecules by learning from existing chemical libraries, enabling the design of compounds with optimal binding affinities to disease-specific targets [18]. AI-driven platforms such as DeepChem and ChemGAN have demonstrated the ability to generate synthetic molecules with high bioactivity, expediting the hit-to-lead optimization process [19].

Additionally, structure-based drug design (SBDD) benefits from AI-powered molecular docking simulations. Deep learning models, such as AlphaFold, predict 3D protein structures, improving the identification of potential drug-binding sites [20]. AI-driven virtual screening approaches enable researchers to rapidly evaluate millions of compounds, prioritizing those with the highest therapeutic potential [21]. These advancements have led to the discovery of new kinase inhibitors and monoclonal antibodies, optimizing treatment strategies in oncology and other therapeutic areas [22].

5.2 AI in Drug Repurposing

Drug repurposing, also known as drug repositioning, involves identifying new therapeutic applications for existing drugs. This approach significantly reduces the time and cost required for drug approval since repurposed drugs have already undergone safety and pharmacokinetic evaluations [23]. AI-driven methodologies enable a systematic and large-scale analysis of drug-disease associations by leveraging multi-omics data, real-world evidence (RWE), and biomedical literature mining [24].

Identifying New Indications for Existing Drugs

AI-based drug repurposing leverages ML techniques, such as random forests, support vector machines (SVMs), and deep neural networks (DNNs), to analyze relationships between drugs, targets, and disease phenotypes [25]. Network-based AI models, such as knowledge graphs and graph neural networks (GNNs), map drug-target interactions, identifying hidden connections between approved drugs and alternative cancer indications [26].

For example, AI models trained on gene expression profiles and drug perturbation datasets predict how existing drugs modulate oncogenic pathways, leading to novel repurposing opportunities [27]. AI-driven approaches have also integrated electronic health records (EHRs) and patient omics data to identify off-label uses of FDA-approved drugs, optimizing precision oncology treatments [28].

Examples of AI-Driven Drug Repurposing Successes in Oncology

Several AI-based platforms have successfully identified **new oncology applications** for existing drugs:

1. Thalidomide for Multiple Myeloma: Originally developed as a sedative, AI-driven research identified its immunomodulatory properties, leading to its approval for multiple myeloma treatment by targeting angiogenesis pathways [29].

2. Metformin in Colorectal Cancer: AI-assisted metabolic modeling discovered metformin's anti-tumor activity, demonstrating its role in inhibiting cancer cell proliferation through AMPK pathway activation [30].
3. Propranolol for Angiosarcoma: Deep learning-based drug-target mapping found that propranolol, a beta-blocker, exhibits anti-angiogenic properties, making it effective for treating vascular malignancies [31].
4. Auranofin for Ovarian Cancer: Originally used for rheumatoid arthritis, AI-driven screening identified auranofin's ability to induce oxidative stress in cancer cells, leading to its evaluation in ovarian cancer clinical trials [32].

By leveraging AI in drug repurposing, researchers can rapidly identify cost-effective and clinically validated therapeutic options, expanding the treatment landscape for oncology and other diseases [33].

5.3 Challenges in AI-Driven Drug Discovery and Repurposing

Despite its potential, AI-driven drug discovery and repurposing face several scientific and regulatory challenges that must be addressed before widespread clinical adoption.

Data Biases and Generalizability Issues

AI models rely on large-scale biological and pharmacological datasets, but biases in training data can impact the accuracy and generalizability of AI predictions. Many public drug discovery datasets are biased toward well-studied compounds, limiting the model's ability to predict novel drug candidates beyond existing chemical scaffolds [34]. Additionally, discrepancies in data from different research institutions, such as differences in cell line experiments, gene expression assays, and animal models, introduce variability, making it difficult to achieve consistent AI-driven predictions [35]. Standardizing AI-training datasets and increasing the diversity of molecular libraries will be critical for improving model reliability.

Regulatory Hurdles in AI-Assisted Drug Approvals

The adoption of AI-driven drug discovery in regulatory frameworks remains a major challenge. Agencies like the FDA and EMA require rigorous validation of AI-predicted drug candidates before clinical trials, but the lack of standardized AI validation protocols creates hurdles for AI-assisted drug approvals [36]. Additionally, explainability and transparency in AI decision-making remain concerns, as regulatory agencies demand interpretable evidence for how AI identifies drug-disease relationships [37].

To address these challenges, researchers are working on:

- Developing explainable AI (XAI) frameworks to enhance transparency in AI-driven drug predictions.
- Integrating AI models into regulatory workflows to standardize validation pipelines.
- Encouraging collaborative AI research initiatives between academia, industry, and regulatory bodies to ensure compliance with drug development guidelines.

The future of AI-driven drug discovery and repurposing lies in overcoming these technical and regulatory barriers, ensuring that AI-based therapeutic innovations can be safely and efficiently translated into clinical practice [38].

Table 2: Key AI-Based Drug Discovery Platforms and Their Applications in Oncology

Platform	AI Technique	Application in Oncology
DeepChem	Deep Learning	Molecular property prediction for novel drug design
AlphaFold	Transformer Networks	Protein structure prediction for cancer target discovery
BenevolentAI	Knowledge Graphs	AI-driven drug repurposing for precision oncology
Atomwise	Convolutional Neural Networks (CNNs)	Virtual screening of small-molecule inhibitors
Insilico Medicine	Generative AI Models	De novo drug design for oncology therapeutics
IBM Watson Drug Discovery	NLP and Machine Learning	AI-driven analysis of scientific literature for drug-disease mapping

6. ETHICAL, REGULATORY, AND IMPLEMENTATION CHALLENGES

6.1 Ethical Considerations in AI for Oncology

The integration of artificial intelligence (AI) in oncology presents significant ethical challenges, particularly concerning patient data privacy, algorithmic bias, and decision-making fairness. Given the sensitive nature of genomic and clinical data, AI models must ensure that patient information remains secure, de-identified, and ethically handled throughout AI-driven analyses [20].

Patient Data Privacy and Security Concerns

AI-driven oncology systems rely on large-scale datasets, including electronic health records (EHRs), imaging scans, and multi-omics data, to train predictive models. Ensuring data privacy and security is critical, particularly in compliance with regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. and the General Data Protection Regulation (GDPR) in the EU [21]. Data anonymization techniques, including federated learning and homomorphic encryption, have been proposed to enable AI training without exposing raw patient data [22]. However, cybersecurity risks, including adversarial attacks on AI models, pose ongoing challenges that require robust encryption protocols and real-time anomaly detection [23].

Addressing Bias and Fairness in AI-Driven Decision-Making

Algorithmic bias remains a significant concern in AI-driven oncology, as models trained on non-diverse datasets risk propagating healthcare disparities. AI models developed using limited demographic representation may underperform in minority populations, leading to unequal treatment recommendations [24]. For example, AI-driven melanoma detection algorithms trained predominantly on lighter skin tones have exhibited lower accuracy in detecting malignancies in darker skin tones [25].

To mitigate bias, AI models must incorporate diverse, multi-ethnic datasets and undergo rigorous fairness testing before clinical deployment. Additionally, explainable AI (XAI) techniques, such as SHAP (Shapley Additive Explanations) and counterfactual reasoning, can improve transparency, allowing clinicians to interpret and validate AI-generated treatment recommendations [26].

6.2 Regulatory and Clinical Implementation Challenges

Despite AI's transformative potential in oncology, its clinical adoption is hindered by regulatory hurdles and workflow integration challenges. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines for AI-driven medical applications, emphasizing the need for clinical validation, transparency, and patient safety [27].

FDA and EMA Guidelines for AI in Healthcare

The FDA classifies AI-powered medical devices under Software as a Medical Device (SaMD), requiring rigorous validation through clinical trials and post-market surveillance [28]. The agency's Good Machine Learning Practice (GMLP) framework outlines key principles for AI reliability, generalizability, and real-world performance monitoring [29]. Similarly, the EMA mandates that AI-based diagnostic and therapeutic tools comply with the Medical Device Regulation (MDR) and demonstrate consistent clinical efficacy [30].

One of the key challenges in regulatory approval is AI's continuous learning capability—unlike traditional static algorithms, adaptive AI models evolve over time, necessitating ongoing regulatory oversight and risk assessment [31]. Additionally, AI models must align with ethical AI principles, ensuring that AI augments clinical decision-making rather than replacing human oversight [32].

Integrating AI Models into Clinical Workflows

The implementation of AI-driven oncology tools in hospital settings requires seamless integration with existing clinical workflows. However, several challenges hinder adoption:

1. Interoperability Issues – Many AI models are trained on proprietary datasets, limiting their compatibility with electronic health record (EHR) systems such as Epic, Cerner, and Meditech [33]. Standardizing data exchange formats, such as FHIR (Fast Healthcare Interoperability Resources), is essential for AI integration.
2. Clinician Trust and Adoption – Many oncologists remain skeptical of black-box AI models, preferring interpretable AI solutions that provide clear justifications for treatment recommendations [34].
3. Clinical Validation Gaps – AI models often lack large-scale randomized clinical trials (RCTs) validating their real-world performance, delaying regulatory acceptance and hospital adoption [35].

6.3 Future Policy Recommendations

To facilitate ethical and effective AI adoption in oncology, policymakers and researchers must focus on regulatory standardization, transparency, and clinician training.

Strategies for Improving AI Adoption in Oncology

1. Developing Standardized AI Validation Frameworks – Regulatory agencies should implement clear guidelines for AI benchmarking, ensuring that models undergo real-world performance testing across diverse patient populations [36].
2. Encouraging Federated Learning Initiatives – Global healthcare institutions should collaborate on decentralized AI training, preserving patient privacy while improving AI model generalizability [37].
3. Establishing AI Ethics Committees – Hospitals and research institutions should form AI ethics oversight boards to review algorithmic bias, patient safety risks, and model interpretability concerns [38].

Need for Transparent AI Models and Explainable AI (XAI)

Explainable AI (XAI) must be prioritized to ensure that oncologists can interpret AI recommendations with confidence. Hybrid AI models, combining deep learning with symbolic reasoning, have shown promise in enhancing interpretability while maintaining predictive accuracy [39].

Future AI policy frameworks should mandate transparent AI disclosures, requiring developers to provide detailed documentation on AI training data sources, decision-making logic, and performance metrics [40].

Table 3: Regulatory Considerations for AI Adoption in Oncology and Their Implications

Regulatory Aspect	Key Considerations	Implications for AI in Oncology
AI Model Validation	Clinical trials, post-market surveillance	Ensures AI reliability and real-world performance
Data Privacy Regulations	Compliance with HIPAA, GDPR	Protects patient confidentiality in AI-driven oncology
Algorithmic Bias Review	Fairness testing across diverse patient populations	Reduces healthcare disparities and improves AI fairness
Explainability Standards	Implementation of XAI techniques	Enhances oncologist trust and AI decision transparency
Adaptive AI Oversight	Continuous monitoring of evolving AI models	Addresses risks of AI performance drift in clinical settings

By addressing these ethical, regulatory, and implementation challenges, AI can be responsibly integrated into oncology, driving safer, more equitable, and clinically effective cancer treatment strategies.



Figure 3: AI-driven precision oncology workflow: from biomarker discovery to personalized treatment selection

7. FUTURE DIRECTIONS AND CONCLUSION

7.1 Future Research and Technological Developments

The future of AI-driven oncology is poised for transformative breakthroughs, particularly in predictive cancer diagnostics, personalized therapy selection, and treatment optimization. As AI continues to evolve, next-generation models will integrate real-time patient monitoring, adaptive learning, and multi-omics data fusion, creating more precise and responsive oncology care systems.

Potential AI Breakthroughs in Predictive Oncology

AI models are rapidly advancing early cancer detection and risk prediction through deep learning, biomarker discovery, and AI-enhanced imaging analysis. Future research is expected to focus on:

1. Liquid Biopsy and AI Integration – AI-powered analysis of circulating tumor DNA (ctDNA), exosomes, and protein biomarkers will enable ultra-sensitive detection of cancer at its earliest stages, reducing reliance on invasive biopsies.
2. AI-Driven Cancer Risk Prediction – Reinforcement learning models will improve longitudinal risk assessment, considering patient genetics, lifestyle factors, and environmental exposures to predict cancer susceptibility with unprecedented accuracy.
3. Multi-Omics Data Fusion for Personalized Risk Models – AI will integrate genomic, proteomic, and metabolomic data to build personalized oncological risk scores, guiding preventive strategies and early interventions.
4. Real-Time Cancer Monitoring – AI-powered wearables and digital biomarkers will track cancer progression and treatment response, enabling oncologists to adjust therapies dynamically based on continuous patient data streams.

Integrating Quantum Computing and AI for Cancer Treatment

The integration of quantum computing with AI has the potential to redefine oncology research, solving computational challenges that were previously intractable. Quantum-enhanced AI models will drive advancements in:

1. Molecular Simulations for Drug Discovery – Quantum computing will accelerate molecular docking simulations, optimizing drug-target interactions with unprecedented speed, enabling faster oncology drug development.
2. AI-Quantum Hybrid Models for Precision Oncology – Quantum-enhanced AI will improve multi-omics analysis, uncovering nonlinear relationships between genetic mutations and treatment responses, leading to more precise therapeutic recommendations.
3. Breakthroughs in Radiotherapy Optimization – Quantum AI models will optimize radiotherapy dose planning, reducing damage to healthy tissues while maximizing tumor control.
4. Ultra-Complex Predictive Models – Quantum-enhanced deep learning models will process massive cancer datasets in parallel, improving accuracy in cancer risk modeling, tumor classification, and AI-assisted diagnostics.

These technological advancements will elevate AI’s role in oncology, ensuring earlier diagnoses, highly personalized treatments, and optimized therapeutic strategies.

7.2 Summary and Final Thoughts

Key Takeaways from the Study

This study explored the transformative role of AI in oncology, spanning diagnostics, treatment selection, drug discovery, and clinical decision support. The key findings emphasize that:

- AI is redefining precision oncology, integrating multi-omics, radiomics, and computational modeling to optimize early detection, risk prediction, and treatment personalization.
- AI-driven biomarker discovery is enhancing cancer diagnostics and therapeutic stratification, reducing trial-and-error treatment approaches.
- Machine learning and reinforcement learning are being leveraged for drug repurposing, clinical trial optimization, and adaptive therapy selection, ensuring more effective and patient-centric cancer care.
- AI in oncology faces challenges, including bias in datasets, regulatory hurdles, ethical concerns, and model interpretability, requiring further research and refinement to ensure safe and equitable clinical deployment.

Call for Multidisciplinary Collaboration in AI-Driven Oncology

The successful integration of AI in oncology requires a multidisciplinary approach, bringing together oncologists, data scientists, AI engineers, regulatory bodies, and policymakers. Key areas for collaboration include:

- Developing standardized AI validation frameworks to enhance model reliability and real-world performance.
- Expanding federated learning initiatives to create globally diverse AI-driven cancer research collaborations.
- Ensuring transparent and explainable AI (XAI) to improve clinician trust and regulatory acceptance.
- Integrating AI with real-world data (RWD) to refine clinical decision-making models.

As AI continues to advance, a unified, multidisciplinary effort will be essential in bridging technological innovation with clinical application, ultimately revolutionizing cancer care and improving patient outcomes.

REFERENCE

1. Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. Computational and structural biotechnology journal. 2020 Jan 1;18:2300-11.
2. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Medical Oncology. 2022 Jun 15;39(8):120.
3. Ali H. Artificial intelligence in multi-omics data integration: Advancing precision medicine, biomarker discovery and genomic-driven disease interventions.
4. Xu J, Yang P, Xue S, Sharma B, Sanchez-Martin M, Wang F, Beaty KA, Dehan E, Parikh B. Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives. Human genetics. 2019 Feb 8;138(2):109-24.
5. Sherani AM, Khan M, Qayyum MU, Hussain HK. Synergizing AI and Healthcare: Pioneering advances in cancer medicine for personalized treatment. International Journal of Multidisciplinary Sciences and Arts. 2024 Feb 4;3(2):270-7.
6. Mathema VB, Sen P, Lamichhane S, Orešič M, Khoomrung S. Deep learning facilitates multi-data type analysis and predictive biomarker discovery in cancer precision medicine. Computational and Structural Biotechnology Journal. 2023 Jan 1;21:1372-82.

7. Liao J, Li X, Gan Y, Han S, Rong P, Wang W, Li W, Zhou L. Artificial intelligence assists precision medicine in cancer treatment. Frontiers in oncology. 2023 Jan 4;12:998222.
8. Wei L, Niraula D, Gates ED, Fu J, Luo Y, Nyflot MJ, Bowen SR, El Naqa IM, Cui S. Artificial intelligence (AI) and machine learning (ML) in precision oncology: a review on enhancing discoverability through multiomics integration. The British Journal of Radiology. 2023 Oct 1;96(1150):20230211.
9. Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Frontiers in Pharmacology. 2020 Aug 12;11:1177.
10. Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. NPJ precision oncology. 2019 Feb 25;3(1):6.
11. Boniolo F, Dorigatti E, Ohnmacht AJ, Saur D, Schubert B, Menden MP. Artificial intelligence in early drug discovery enabling precision medicine. Expert Opinion on Drug Discovery. 2021 Sep 2;16(9):991-1007.
12. Bhalla S, Laganà A. Artificial intelligence for precision oncology. Computational methods for precision oncology. 2022 Mar 1:249-68.
13. Khalighi S, Reddy K, Midya A, Pandav KB, Madabhushi A, Abedalthagafi M. Artificial intelligence in neuro-oncology: advances and challenges in brain tumor diagnosis, prognosis, and precision treatment. NPJ precision oncology. 2024 Mar 29;8(1):80.
14. Restrepo JC, Dueñas D, Corredor Z, Liscano Y. Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment. Cancers. 2023 Jul 3;15(13):3474.
15. Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015 Mar 1;64(3):S16-21.
16. Vadapalli S, Abdelhalim H, Zeeshan S, Ahmed Z. Artificial intelligence and machine learning approaches using gene expression and variant data for personalized medicine. Briefings in bioinformatics. 2022 Sep;23(5):bbac191.
17. Schork NJ. Artificial intelligence and personalized medicine. Precision medicine in Cancer therapy. 2019:265-83.
18. Saxena S, Jena B, Gupta N, Das S, Sarmah D, Bhattacharya P, Nath T, Paul S, Fouda MM, Kalra M, Saba L. Role of artificial intelligence in radiogenomics for cancers in the era of precision medicine. Cancers. 2022 Jun 9;14(12):2860.
19. Wang Z, Liu Y, Niu X. Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology. InSeminars in Cancer Biology 2023 Aug 1 (Vol. 93, pp. 83-96). Academic Press.
20. Corti C, Cobanaj M, Dee EC, Criscitiello C, Tolaney SM, Celi LA, Curigliano G. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. Cancer Treatment Reviews. 2023 Jan 1;112:102498.
21. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision medicine, AI, and the future of personalized health care. Clinical and translational science. 2021 Jan;14(1):86-93.
22. Elemento O, Leslie C, Lundin J, Tourassi G. Artificial intelligence in cancer research, diagnosis and therapy. Nature Reviews Cancer. 2021 Dec;21(12):747-52.

23. Fawaz A, Ferraresi A, Isidoro C. Systems biology in cancer diagnosis integrating omics technologies and artificial intelligence to support physician decision making. Journal of Personalized Medicine. 2023 Nov 10;13(11):1590.
24. Bukunmi Temiloluwa Ofili, Steven Chukwuemeka Ezeadi, Taiwo Boluwatife Jegede. Securing U.S. national interests with cloud innovation: data sovereignty, threat intelligence and digital warfare preparedness. *Int J Sci Res Arch*. 2024;12(01):3160-3179. doi: 10.30574/ijsra.2024.12.1.1158.
25. Adeyinka Orelaja, Resty Nasimbwa, Omoyin Damilola David. Enhancing cybersecurity infrastructure: A case study on safeguarding financial transactions. *Aust J Sci Technol*. 2024 Sep;8(3). Available from: https://www.aujst.com/vol-8-3/1.pdf
26. Chukwunweike JN, Praise A, Bashirat BA, 2024. Harnessing Machine Learning for Cybersecurity: How Convolutional Neural Networks are Revolutionizing Threat Detection and Data Privacy. https://doi.org/10.55248/gengpi.5.0824.2402.
27. Chiamaka Daniella Okenwa, Adenike F. Adeyemi, Adeyinka Orelaja, Resty Nasimbwa. Predictive analytics in financial regulation: advancing compliance models for crime prevention. *IOSR J Econ Financ*. 2024 Jul-Aug;15(4):1-7. doi: 10.9790/5933-1504030107.
28. Ahmed Z. Multi-omics strategies for personalized and predictive medicine: past, current, and future translational opportunities. Emerging topics in life sciences. 2022 Mar 2;6(2):215-25.
29. Biswas N, Chakrabarti S. Artificial intelligence (AI)-based systems biology approaches in multi-omics data analysis of cancer. Frontiers in oncology. 2020 Oct 14;10:588221.
30. Ahmed Z. Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis. Human genomics. 2020 Oct 2;14(1):35.
31. Chakravarty K, Antontsev V, Bundey Y, Varshney J. Driving success in personalized medicine through AI-enabled computational modeling. Drug Discovery Today. 2021 Jun 1;26(6):1459-65.
32. Asif S, Ahmad N. Machine Learning in Genomic Analysis: Transforming Precision Medicine and Biomedical Research Through AI-Powered Innovations.
33. Chukwunweike JN, Busayo LA, Dolapo H, Salaudeen, Sydney A and Adewale MF. Advancing Tuberculosis Prediction: Integrating AI, CNN, and MATLAB for Enhanced Predictive Modelling. DOI: 10.7753/IJCATR1308.1013
34. Mumtaz H, Saqib M, Jabeen S, Muneeb M, Mughal W, Sohail H, Safdar M, Mehmood Q, Khan MA, Ismail SM. Exploring alternative approaches to precision medicine through genomics and artificial intelligence–a systematic review. Frontiers in medicine. 2023 Oct 2;10:1227168.
35. Rasool S, Ali M, Shahroz HM, Hussain HK, Gill AY. Innovations in AI-powered healthcare: Transforming cancer treatment with innovative methods. BULLET: Jurnal Multidisiplin Ilmu. 2024;3(1):118-28.
36. Rodríguez-Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. Journal of internal medicine. 2015 Feb;277(2):201-17.
37. Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, Ock CY, Kim S. Artificial intelligence in breast cancer diagnosis and personalized medicine. Journal of Breast Cancer. 2023 Oct 17;26(5):405.
38. Ahluwalia P, Ballur K, Leeman T, Vashisht A, Singh H, Omar N, Mondal AK, Vaibhav K, Baban B, Kolhe R. Incorporating novel technologies in precision oncology for colorectal cancer: advancing personalized

medicine. Cancers. 2024 Jan 23;16(3):480.

39. Kann BH, Hosny A, Aerts HJ. Artificial intelligence for clinical oncology. Cancer Cell. 2021 Jul 12;39(7):916-27.
40. de Jong J, Cutcutache I, Page M, Elmoufti S, Dilley C, Fröhlich H, Armstrong M. Towards realizing the vision of precision medicine: AI based prediction of clinical drug response. Brain. 2021 Jun 1;144(6):1738-50.